Anzeige
Meldung des Tages: +330 %: Warum Wolfram plötzlich explodiert und der Wolfram-Schock erst beginnen könnte

Invesco Water Resources ETF Registered Shares News

ETF
WKN:  A2JNQQ ISIN:  US46137V1420 US-Symbol:  PHO
58,94 €
+0,81 €
+1,39%
10.04.26
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Invesco Water Resources ETF Registered Shares News

07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire
13.04.26 - PR Newswire
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Photocure ASA: Update on Regulatory Classification for OAY Equipment PR Newswire
16.03.26 - PR Newswire
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway PR Newswire
16.03.26 - PR Newswire
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
27.02.26 - PR Newswire
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire
19.11.25 - PR Newswire
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management PR ...
29.10.25 - PR Newswire
Photocure ASA: Results for the third quarter of 2025
Photocure ASA: Results for the third quarter of 2025 PR Newswire
29.10.25 - PR Newswire
Photocure ASA: Results for the third quarter of 2025
Photocure ASA: Results for the third quarter of 2025 PR Newswire
15.10.25 - PR Newswire
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy PR Newswire
30.07.25 - PR Newswire
Photocure ASA: Results for the second quarter of 2025
Photocure ASA: Results for the second quarter of 2025 PR Newswire
30.07.25 - PR Newswire
Photocure ASA: Results for the second quarter of 2025
Photocure ASA: Results for the second quarter of 2025 PR Newswire

Newssuche

Videos

newspaper
05.05.26 -0,83%
Technical Trading: DAX 25%-Crash!?
DAX Short Typ: Open End Turbo WKN: VG58BK Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »